BridgeBio Pharma Inc (BBIO)vsMerck & Company Inc (MRK)
BBIO
BridgeBio Pharma Inc
$83.54
-1.68%
HEALTHCARE · Cap: $15.94B
MRK
Merck & Company Inc
$129.79
-0.44%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 11240% more annual revenue ($65.77B vs $579.96M). MRK leads profitability with a 13.6% profit margin vs -124.4%. MRK earns a higher WallStSmart Score of 50/100 (D+).
BBIO
Avoid31
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.2%
Fair Value
$529.47
Current Price
$83.54
$445.93 discount
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$129.79
$48.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 66.8% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -1790.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BBIO
The strongest argument for BBIO centers on Revenue Growth, Debt/Equity. Revenue growth of 66.8% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BBIO
The primary concerns for BBIO are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
BBIO profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
BBIO carries more volatility with a beta of 0.95 — expect wider price swings.
BBIO is growing revenue faster at 66.8% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). BBIO offers better value entry with a 84.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BridgeBio Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?